{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:47:48Z","timestamp":1788410868780,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,4,23]],"date-time":"2013-04-23T00:00:00Z","timestamp":1366675200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1038\/bjc.2013.183","type":"journal-article","created":{"date-parts":[[2013,4,23]],"date-time":"2013-04-23T19:58:41Z","timestamp":1366747121000},"page":"1771-1777","source":"Crossref","is-referenced-by-count":94,"title":["Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO"],"prefix":"10.1038","volume":"108","author":[{"given":"I","family":"Ray-Coquard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Favier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Roemer-Becuwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Bougnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Floquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Plantade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Paraiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Pujade-Lauraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,23]]},"reference":[{"key":"BFbjc2013183_CR1","unstructured":"ARIAD Pharmaceuticals Inc. ARIAD presents positive efficacy data on AP23573, novel mTOR inhibitor, in phase 2 metastatic endometrial cancer trial [press release]. Available http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=118422&p=irol-newsArticle_print&ID=1010401&highlight= (accessed 16 February 2012)."},{"key":"BFbjc2013183_CR2","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","volume":"30","author":"T Bachelot","year":"2012","unstructured":"Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Bebled M, Spa\u00ebth D, Legouffe E, Allouache D, El Khouri C, Pujade-Lauraine E (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth fact receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30: 2718\u20132724.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013183_CR3","first-page":"2025","volume":"30","author":"M Block","year":"2010","unstructured":"Block M, Fister S, Emons G, Seeber S, Grundker C, Gunthert AR (2010) Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells. Anticancer Res 30: 2025\u20132031.","journal-title":"Anticancer Res"},{"key":"BFbjc2013183_CR4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/modpathol.2010.44","volume":"23","author":"L Catasus","year":"2010","unstructured":"Catasus L, D'Angelo E, Pons C, Espinosa I, Prat J (2010) Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations. Mod Pathol 23: 694\u2013702.","journal-title":"Mod Pathol"},{"key":"BFbjc2013183_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/modpathol.2009.5","volume":"22","author":"L Catasus","year":"2009","unstructured":"Catasus L, Gallardo A, Cuatrecasas M, Prat J (2009) Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 22: 522\u2013529.","journal-title":"Mod Pathol"},{"issue":"Suppl","key":"BFbjc2013183_CR6","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1200\/jco.2007.25.18_suppl.5516","volume":"25","author":"N Colombo","year":"2007","unstructured":"Colombo N, McMeekin S, Schwartz P, Kostka J, Sessa C, Gehrig P, Holloway R, Braly P, Matei D, Einstein M (2007) A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol 25 (Suppl): Abstr. 5516.","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"BFbjc2013183_CR7","doi-asserted-by":"crossref","first-page":"vi35","DOI":"10.1093\/annonc\/mdr374","volume":"22","author":"N Colombo","year":"2011","unstructured":"Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, Sessa C (2011) Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol 22 (Suppl 6): vi35\u2013vi39.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"BFbjc2013183_CR8","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/S0020-7292(06)60031-3","volume":"95","author":"WT Creasman","year":"2006","unstructured":"Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S (2006) Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95 (Suppl 1): S105\u2013S143.","journal-title":"Int J Gynaecol Obstet"},{"key":"BFbjc2013183_CR9","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893\u20132917.","journal-title":"Int J Cancer"},{"issue":"Suppl","key":"BFbjc2013183_CR10","doi-asserted-by":"publisher","first-page":"5014","DOI":"10.1200\/jco.2011.29.15_suppl.5014","volume":"29","author":"GF Fleming","year":"2011","unstructured":"Fleming GF, Filiaci V L, Hanjani P, Burke JJ II, Davidson SA, Leslie KK, Zaino RJ (2011) Hormonal therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group Trial #248. J Clin Oncol 29 (Suppl)): : Abstr. 5014.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013183_CR11","doi-asserted-by":"publisher","first-page":"5932","DOI":"10.1158\/1078-0432.CCR-06-1375","volume":"12","author":"MP Hayes","year":"2006","unstructured":"Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ, Ellenson LH (2006) PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 12: 5932\u20135935.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2013183_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdl417","volume":"18","author":"CE Humber","year":"2007","unstructured":"Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, Green JA (2007) Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 18: 409\u2013420.","journal-title":"Ann Oncol"},{"key":"BFbjc2013183_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277\u2013300.","journal-title":"CA Cancer J Clin"},{"key":"BFbjc2013183_CR14","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.humpath.2010.01.030","volume":"42","author":"B Konopka","year":"2011","unstructured":"Konopka B, Janiec-Jankowska A, Kwiatkowska E, Najmola U, Bidzinski M, Olszewski W, Goluda C (2011) PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors. Hum Pathol 42: 1710\u20131719.","journal-title":"Hum Pathol"},{"key":"BFbjc2013183_CR15","first-page":"1627","volume":"32","author":"H Liu","year":"2012","unstructured":"Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J (2012) Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer ceels to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res 32: 1627\u20131637.","journal-title":"Anticancer Res"},{"issue":"Suppl","key":"BFbjc2013183_CR16","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1200\/jco.2011.29.15_suppl.5013","volume":"29","author":"H Mackay","year":"2011","unstructured":"Mackay H, Welch S, Tsao MS, Biagi JJ, Elit L, Ghatage P, Martin LA, Tonkin KS, Ellard S, Lau SK, McIntosh L, Eisenhauer EA, Oza AM (2011) Phase II study of oral ridaforolimus in patients with metastatic and\/or locally advanced recurrent endometrial cancer. J Clin Oncol 29 (Suppl): Abstr. 5013.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013183_CR17","doi-asserted-by":"publisher","first-page":"247.e1","DOI":"10.1016\/j.ajog.2006.10.872","volume":"196","author":"MR Milam","year":"2007","unstructured":"Milam MR, Celestino J, Wu W, Broaddus RR, Schmeler KM, Slomovitz BM, Soliman PT, Gershenson DM, Wang H, Ellenson LH, Lu KH (2007) Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am J Obstet Gynecol 196: 247.e1\u2013247.e5.","journal-title":"Am J Obstet Gynecol"},{"key":"BFbjc2013183_CR18","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116: 4256\u20134265.","journal-title":"Cancer"},{"key":"BFbjc2013183_CR19","unstructured":"National Cancer Institute (2006) Common terminology criteria for adverse events v3.0 (CTCAE). National Cancer Institute Web site., http:\/\/ctep.cancer.gov\/reporting\/ctc_v30.html ."},{"key":"BFbjc2013183_CR20","unstructured":"National Comprehensive Cancer Network (2012) NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. V.3.2012, National Comprehensive Cancer Network Web site http:\/\/www.nccn.org ."},{"key":"BFbjc2013183_CR21","doi-asserted-by":"publisher","first-page":"10669","DOI":"10.1158\/0008-5472.CAN-05-2620","volume":"65","author":"K Oda","year":"2005","unstructured":"Oda K, Stokoe D, Taketani Y, McCormick F (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65: 10669\u201310673.","journal-title":"Cancer Res"},{"key":"BFbjc2013183_CR22","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","volume":"29","author":"AM Oza","year":"2011","unstructured":"Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA (2011a) Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 29: 3278\u20133285.","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"BFbjc2013183_CR23","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1200\/jco.2011.29.15_suppl.5009","volume":"29","author":"AM Oza","year":"2011","unstructured":"Oza AM, Poveda A, Clamp AR, Pignata S, Scambia G, Del Campo JM, McCormack M, Sevcik L, Schwartz BM, Guan S, Lee R, Cheng JD, Haluska FG (2011b) A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotherapy (P) in female adult patients with advanced endometrial carcinoma. J Clin Oncol 29 (Suppl): Abstr. 5009.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013183_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ygyno.2008.01.028","volume":"109","author":"D Pectasides","year":"2008","unstructured":"Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, Psyrri A, Gaglia A, Kassanos D, Gouveris P, Panayiotidis J, Fountzilas G, Economopoulos T (2008) Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol 109: 250\u2013254.","journal-title":"Gynecol Oncol"},{"key":"BFbjc2013183_CR25","doi-asserted-by":"publisher","first-page":"10320","DOI":"10.1073\/pnas.171060098","volume":"98","author":"K Podsypanina","year":"2001","unstructured":"Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L, Parsons R (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70\/S6 kinase activity in Pten+\/\u2212 mice. Proc Natl Acad Sci USA 98: 10320\u201310325.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbjc2013183_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1158\/1078-0432.CCR-10-0540","volume":"17","author":"ML Rudd","year":"2011","unstructured":"Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, Bell DW (2011) A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 17: 1331\u20131340.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2013183_CR27","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1470-2045(11)70230-3","volume":"12","author":"P Schoffski","year":"2011","unstructured":"Schoffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, Krarup-Hansen A, Grunwald V, Sciot R, Dumez H, Blay JY, Le CA, Wanders J, Hayward C, Marreaud S, Ouali M, Hohenberger P (2011) Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncology 12: 1045\u20131052.","journal-title":"Lancet Oncology"},{"key":"BFbjc2013183_CR28","doi-asserted-by":"publisher","first-page":"e37431","DOI":"10.1371\/journal.pone.0037431","volume":"7","author":"K Shoji","year":"2012","unstructured":"Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y (2012) Genotype-dependent efficacy of a dual PI3K\/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS ONE 7: e37431.","journal-title":"PLoS ONE"},{"key":"BFbjc2013183_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1\u201310.","journal-title":"Control Clin Trials"},{"key":"BFbjc2013183_CR30","unstructured":"Slomovitz BM, Brown J, Johnston TA, Mura D, Levenback C, Wolf J, Adler KR, Lu KH, Coleman RL (2011) A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol (2011) (Suppl): Abstr. 5012."},{"key":"BFbjc2013183_CR31","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1002\/cncr.25515","volume":"116","author":"BM Slomovitz","year":"2010","unstructured":"Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, Wolf J (2010) A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116: 5415\u20135419.","journal-title":"Cancer"},{"key":"BFbjc2013183_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1525-1438.2006.00746.x","volume":"17","author":"MA Sovak","year":"2007","unstructured":"Sovak MA, Dupont J, Hensley ML, Ishill N, Gerst S, Abu-Rustum N, Anderson S, Barakat R, Konner J, Poyner E, Sabbatini P, Spriggs DR, Aghajanian C (2007) Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer 17: 197\u2013203.","journal-title":"Int J Gynecol Cancer"},{"key":"BFbjc2013183_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205\u2013216.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"BFbjc2013183_CR34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11523-012-0242-9","volume":"8","author":"Olivier Tr\u00e9dan","year":"2012","unstructured":"Tr\u00e9dan O, Treilleux I, Wang Q, Gane N, Pissaloux D, Bonnin N, Petit T, Cretin J, Bonichon-Lamichhane N, Priou F, Lavau-Denes S, Mari V, Freyer G, Lebrun D, Alexandre J, Ray-Coquard I (2012) Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO study. Target Oncol e-pub ahead of print 13 December 2012; doi:10.1007\/s11523-012-0242-9.","journal-title":"Targeted Oncology"},{"key":"BFbjc2013183_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.17077\/2154-4751.1103","volume":"2","author":"S Yang","year":"2011","unstructured":"Yang S, Xiao Z, Meng X, Leslie K (2011) Combination therapy with mTOR and PI3 kinase inhibitors is broadly synergistic in a wide variety of endometrial cancer cells. Proc Obstet Gynecol 2: 6.","journal-title":"Proc Obstet Gynecol"},{"key":"BFbjc2013183_CR36","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514\u2013523.","journal-title":"N Engl J Med"},{"key":"BFbjc2013183_CR37","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1002\/cncr.26165","volume":"117","author":"AX Zhu","year":"2011","unstructured":"Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP (2011) Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 117: 5094\u20135102.","journal-title":"Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2013183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2013183","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2013183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:14:08Z","timestamp":1684415648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2013183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,23]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["BFbjc2013183"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2013.183","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,23]]}}}